|36.57||+0.5800||+1.61%||Vol 2.55M||1Y Perf 2.74%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||-0.07 -0.19%|
|Target Price||41.73||Analyst Rating||Moderate Sell 3.71|
|Potential %||14.11||Finscreener Ranking||★★+ 47.18|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 53.44|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★ 51.71|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★+ 36.05|
|Price Range Ratio 52W %||51.53||Earnings Rating||Strong Buy|
|Market Cap||74.88B||Earnings Date||1st Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.09|
|EPS Growth Next 5 Years %||5.40|
|Avg. Weekly Volume||2.25M|
|Avg. Monthly Volume||3.32M|
|Avg. Quarterly Volume||3.50M|
GlaxoSmithKline PLC (NYSE: GSK) stock closed at 36.57 per share at the end of the most recent trading day (a 1.61% change compared to the prior day closing price) with a volume of 2.55M shares and market capitalization of 74.88B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 99437 people. GlaxoSmithKline PLC CEO is Emma N. Walmsley.
The one-year performance of GlaxoSmithKline PLC stock is 2.74%, while year-to-date (YTD) performance is 4.07%. GSK stock has a five-year performance of -12.66%. Its 52-week range is between 33.2 and 39.74, which gives GSK stock a 52-week price range ratio of 51.53%
GlaxoSmithKline PLC currently has a PE ratio of 4.30, a price-to-book (PB) ratio of 4.49, a price-to-sale (PS) ratio of 2.61, a price to cashflow ratio of 7.00, a PEG ratio of 0.80, a ROA of 19.50%, a ROC of 39.71% and a ROE of 110.12%. The company’s profit margin is 61.49%, its EBITDA margin is 25.50%, and its revenue ttm is $27.04 Billion , which makes it $13.21 revenue per share.
Of the last four earnings reports from GlaxoSmithKline PLC, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.09 for the next earnings report. GlaxoSmithKline PLC’s next earnings report date is -.
The consensus rating of Wall Street analysts for GlaxoSmithKline PLC is Moderate Sell (3.71), with a target price of $41.73, which is +14.11% compared to the current price. The earnings rating for GlaxoSmithKline PLC stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
GlaxoSmithKline PLC has a dividend yield of 3.67% with a dividend per share of $1.27 and a payout ratio of 91.00%.
GlaxoSmithKline PLC has a Buy technical analysis rating based on Technical Indicators (ADX : 7.63, ATR14 : 0.51, CCI20 : 172.05, Chaikin Money Flow : 0.16, MACD : 0.12, Money Flow Index : 52.96, ROC : 5.66, RSI : 62.91, STOCH (14,3) : 99.26, STOCH RSI : 1.00, UO : 66.89, Williams %R : -0.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of GlaxoSmithKline PLC in the last 12-months were: Anne Beal (Buy at a value of $22 225), Charles A. Bancroft (Buy at a value of $150 158), Elizabeth McKee Anderson (Buy at a value of $16 320), Emma N. Walmsley (Buy at a value of $630), Emma N. Walmsley (Sold 205 265 shares of value $3 036 792 ), Hal V Barron (Buy at a value of $24 316), Harry C Dietz (Buy at a value of $22 225), Iain James Mackay (Sold 19 292 shares of value $287 233 ), Jesse Goodman (Buy at a value of $24 748), Jonathan Richard Symonds (Buy at a value of $59 137), Urs Rohner (Buy at a value of $18 491), Victoria Anne Whyte (Buy at a value of $343), Vishal Sikka (Buy at a value of $48 906)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.